Emerging research suggest Retatrutide , a dual agonist targeting both incretin and GIP , appears to provide a significant step forward for body management . Preliminary patient investigations have shown considerable losses in visceral mass , possibly surpassing current body composition medications . Despite this, further assessment is required to f